Mean Platelet Volume in Remitter Patients with Inflammatory Bowel Disease

AIKAN, Erhan; KARAKAŞ, Mustafa Serkan; Yıldırım, Bülent

Mean Platelet Volume in Remitter Patients with Inflammatory Bowel Disease

Erhan AIKAN, (Akdeniz University)

Mustafa Serkan KARAKAŞ, (Niğde State Hospital)

Bülent YILDIRIM (Akdeniz University)

İnönü Üniversitesi Turgut Özal Tıp Merkezi Dergisi

3 1

Yıl: 2013 Cilt: 20 Sayı: 4 Sayfa Aralığı: 295 - 299 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Mean Platelet Volume in Remitter Patients with Inflammatory Bowel Disease

Öz:

Ülseratif kolit ve Chron hastalığını içeren inflamatuvar barsak hastalıkları gastrointestinal sistemin kronik inflamatuvar bir hastalığıdır. lnflamatuvar barsak hastalıkları olan hastalarda tromboembolik komplikasyonlarda önemli oranda artışlar saptanmıştır. Trombosit aktivasyon ve agregasyonu, aterotromboz patofizyolojisinde önemli bir rol oynamaktadır. Trombosit aktivasyonunun bir diğer göstergesi olan ortalama trombosit hacmi, aterotromboz için yeni keşfedilmiş ve giderek yaygın kullanılan bir laboratuar parametresidir. Bu çalışmada inflamatuvar barsak hastalıkları ile ortalama trombosit hacmi arasındaki ilişkiyi araştırdık. Gereç ve Yöntemler: Çalışmaya en az aydır remisyonda olan 17 Chron hastası ve 23 ülseratif kolit hastası ile 40 sağlıklı birey alındı. Bilinen aterosklerozu, diabeti, hipertansiyonu, hiperlipidemisi, böbrek yetmezliği oIanIar, sigara içenler, 45 yaşın üzerindeki hastalar ile aydan daha önce tanı almış hastalar ile remisyonda olmayanlar çalışmadan çıkarıldı. Hastalar ve kontrol grubunda ortalama trombosit hacmi değerleri karşılaştırıldı. Bulgular: lBH ve kontrol grubunun demografik değerlerinde farklılık saptanmadı. lBH olanlarda kontrol grubuna kıyasla ortalama trombosit hacmi değerlerinin daha yüksek olduğu görüldü (8.17:0.71 vs.7.76:0.48 fl; p=0.004). ülseratif kolit ve chron hastaları ortalama trombosit hacmi değerleri açısından karşılaştırıldığında fark saptanmadı (8.26:0.82 vs.8.0SiO.52 fl; p=O.3). Sonuç: Çalışmamızın sonuçları inflamatuvar barsak hastalıklarında trombosit aktivasyonunda artış olduğunu ve lBH'da aterotromboz riskinde artış olduğunu göstermektedir.

Anahtar Kelime:

Konular: Genel ve Dahili Tıp

Inflamatuvar Barsak Hastalığı Olan Remisyondaki Hastalarda Ortalama Trombosit Hacminin Değerlendirilmesi

Öz:

Inflammatory bowel diseases (IBD) including ulcerative colitis (UC) and Crohn's disease (CD) are chronic inflammatory diseases of thegastrointestinal tract. An increase in thromboembolic complications has been observed among patients with IBD. Platelet activation andaggregation play an important role in the pathophysiology of atherotrombosis. Mean platelet volume (MPV), determinant of plateletactivation, is one of the newly identified risk factors for atherothrombosis. In this study, we investigated the possible relationship betweenIBD and MPV.Material and Methods: The study enrolled 17 CD and 23 UC patients who were in remission for at least months and control group of40 healthy subjects. Patients with established atherosclerosis, diabetes, hypertension, hyperlipidemia, renal failure, smokers, patients agedover 45, patients diagnosed within less than months and non—remitters were excluded from the study. MPV values were obtained.Results: Comparison of IBD and control groups with respect to demographic data did not yield statistically significant differences.However,statistically significant higher MPV values were observed for IBD patients versus control group (8.17:0.71 vs.7.76i0.48 fl;p=0.004). Comparison of UC and CD individually did not show any differences in MPV values (8.26:0.82 vs.8.05i0.52 fl; p=O.3).Conclusions: Our results show increased platelet activation in IBD and an increased risk for atherotrombosis in IBD patients.

Anahtar Kelime:

Konular: Genel ve Dahili Tıp

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Sands BE. Crohn's Disease. Feldman M. Sleisenger Fordtran's Gastrointestinal and Liver Disease, Eighth ed. Saunders: 2006. p.2459-98.
2. Su C, Lichtenstein GR. Ulcerative Colitis. Feldman M. Sleisenger Fordtran's Gastrointestinal and Liver Disease, Eighth ed. Saunders: 2006. p.2499—548.
3. Akbulut S, Altiparmak E, Topal F, Ozaslan E, Kucukazman M, Yonem O. Increased levels of homocysteine in patients with ulcerative colitis. World Gastroenterol 2010;16:2411- 16.
4. Souto JC, Martinez E, Roca M, Mateo J, Pujol J, Gonzalez D, et al. Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease. Dig Dis Sci 1995;40:1883-9.
5. Collins CE, Rampton DS. Platelet dysfunction: new dimension in inflammatory bowel disease. Gut 1995;36:5-8.
6. Harries AD, Fitzsimons E, Fifield R, Dew MJ, Rhoades J. Platelet count: simple measure of activity in Crohn's disease. Br Med (Clin Res Ed) 1983;286:1476.
7. Tsiara S, Elisaf M, Jagroop |A, Mikhailidis DP. Platelets as predictors of vascular risk: is there practical index of platelet activity? Clin Appl Thromb Hemost 2003;9:177—90.
8. Martin JF. Platelet heterogeneity in vascular disease. ln: Martin JF, Trowbridge EA (eds) Platelet heterogeneity: biology and pathology. Springer-Verlag: London: 1990. p. 205—6.
9. Martin JF, Trowbridge EA, Salmon GL, Plumb J. The biological significance of platelet volume: its relationship to bleeding time, platelet thromboxane BZ production and megakaryocyte nuclear DNA concentration. Thromb Res 1983;32:443—60.
10. Jakubowski JA, Thompson CB, Vaillancourt R, Valeri CR, Deykin D. Arachidonic acid metabolism by platelets of differing size. BrJ Haematol 1983;5:503—11.
11. Park Y, Schoene N, Haris W. Mean platelet volume as an indicator of platelet activation: methodological issues. Platelets 2002;13:301—6.
12. Vizioli L, Muscari S, Muscari A. The relationship of mean platelet volume with the risk and prognosis of cardiovascular diseases. Int Clin Pract 2009;63:1509—15.
13. Kayahan H, Akarsu M, Ozcan MA, Demir S, Ates H, Unsal B, et al. Reticulated platelet levels in patients with ulcerative colitis. lntJ Colorectal Dis 2007;22:1429—35.
14. Rellecke P, Strauer BE. Chronic inflammatory bowel disease and cardiovascular complications. Med Klin (Munich) 2006;101 Suppl 1:56—60.
15. Khandekar MM, Khurana AS, Deshmukh SD, Kakrani AL, Katdare AD, Inamdar AK. Platelet volume indices in patients with coronary artery disease and acute myocardial infarction: an Indian scenario. Clin Pathol 2006;59:146-9.
16. Dogan Y, Soylu A, Eren GA, Poturoglu S, Dolapcioglu C, Sonmez K, et al. Evaluation of OT and wave dispersion and mean platelet volume among inflammatory bowel disease patients. Int Med Sci 2011;8:540—6.
17. Yüksel O, Helvaci K, Başar O, Köklü S, Caner S, Helvaci N, et al. An overlooked indicator of disease activity in ulcerative colitis: volume. Platelets 2009;20:277-81.
Kapsoritakis AN, Koukourakis MI, Sfiridaki A, Potamianos SP, Kosmadaki MG, Koutroubakis |E, et al. Mean platelet volume: useful marker of inflammatory bowel disease activity. Am Gastroenterol. 2001;96:776—81.
Webberley MJ, Hart MT, Melikian V. Thromboembolism in mean platelet inflammatory bowel disease: role of platelets. Gut 1993;34:247-51.
Bath PM, Butterworth RJ. Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrinolysis 1996;7z157—6’l.
Buttervvorth RJ, Bath PM. The relationship between mean platelet volume, stroke subtype and clinical outcome. Platelets 1998;92359—64.
Acikgoz N, Karincaoglu Y, Ermis N, Yagmur J, Atas H, Kurtoglu E, et al. Increased mean platelet volume in Behçet's disease with thrombotic tendency. Tohoku Exp Med 2010;221:119-23.
Collins CE, Rampton DS, Rogers J, Williams NS. Platelet aggregation and neutrophil sequestration in the mesenteric circulation in inflammatory bowel disease. Eur Gastroenterol Hepatol 1997;9z1213—7.

APA	AIKAN E, KARAKAŞ M, Yıldırım B (2013). Mean Platelet Volume in Remitter Patients with Inflammatory Bowel Disease. , 295 - 299.
Chicago	AIKAN Erhan,KARAKAŞ Mustafa Serkan,Yıldırım Bülent Mean Platelet Volume in Remitter Patients with Inflammatory Bowel Disease. (2013): 295 - 299.
MLA	AIKAN Erhan,KARAKAŞ Mustafa Serkan,Yıldırım Bülent Mean Platelet Volume in Remitter Patients with Inflammatory Bowel Disease. , 2013, ss.295 - 299.
AMA	AIKAN E,KARAKAŞ M,Yıldırım B Mean Platelet Volume in Remitter Patients with Inflammatory Bowel Disease. . 2013; 295 - 299.
Vancouver	AIKAN E,KARAKAŞ M,Yıldırım B Mean Platelet Volume in Remitter Patients with Inflammatory Bowel Disease. . 2013; 295 - 299.
IEEE	AIKAN E,KARAKAŞ M,Yıldırım B "Mean Platelet Volume in Remitter Patients with Inflammatory Bowel Disease." , ss.295 - 299, 2013.
ISNAD	AIKAN, Erhan vd. "Mean Platelet Volume in Remitter Patients with Inflammatory Bowel Disease". (2013), 295-299.

APA	AIKAN E, KARAKAŞ M, Yıldırım B (2013). Mean Platelet Volume in Remitter Patients with Inflammatory Bowel Disease. İnönü Üniversitesi Turgut Özal Tıp Merkezi Dergisi, 20(4), 295 - 299.
Chicago	AIKAN Erhan,KARAKAŞ Mustafa Serkan,Yıldırım Bülent Mean Platelet Volume in Remitter Patients with Inflammatory Bowel Disease. İnönü Üniversitesi Turgut Özal Tıp Merkezi Dergisi 20, no.4 (2013): 295 - 299.
MLA	AIKAN Erhan,KARAKAŞ Mustafa Serkan,Yıldırım Bülent Mean Platelet Volume in Remitter Patients with Inflammatory Bowel Disease. İnönü Üniversitesi Turgut Özal Tıp Merkezi Dergisi, vol.20, no.4, 2013, ss.295 - 299.
AMA	AIKAN E,KARAKAŞ M,Yıldırım B Mean Platelet Volume in Remitter Patients with Inflammatory Bowel Disease. İnönü Üniversitesi Turgut Özal Tıp Merkezi Dergisi. 2013; 20(4): 295 - 299.
Vancouver	AIKAN E,KARAKAŞ M,Yıldırım B Mean Platelet Volume in Remitter Patients with Inflammatory Bowel Disease. İnönü Üniversitesi Turgut Özal Tıp Merkezi Dergisi. 2013; 20(4): 295 - 299.
IEEE	AIKAN E,KARAKAŞ M,Yıldırım B "Mean Platelet Volume in Remitter Patients with Inflammatory Bowel Disease." İnönü Üniversitesi Turgut Özal Tıp Merkezi Dergisi, 20, ss.295 - 299, 2013.
ISNAD	AIKAN, Erhan vd. "Mean Platelet Volume in Remitter Patients with Inflammatory Bowel Disease". İnönü Üniversitesi Turgut Özal Tıp Merkezi Dergisi 20/4 (2013), 295-299.